Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Caplen Website

Natasha J. Caplen, Ph.D.

Selected Publications

1)  Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.
Identification of novel molecular regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Breast Cancer Res. 16: R41, 2014.
2)  Camps J, Pitt JJ, Emons G, Hummon AB, Case CM, Grade M, Jones TL, Nguyen QT, Ghadimi BM, Beissbarth T, Difilippantonio MJ, Caplen NJ, Ried T.
Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/ß-catenin pathway in colorectal cancer.
Cancer Res. 73: 2003-13, 2013.
3)  Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Eur. J. Cancer. 49: 3020-8, 2013.
4)  Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Breast Cancer Res. 14: R109, 2012.
5)  Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C.
p53-Dependent induction of PVT1 and miR-1204.
J. Biol. Chem. 287: 2509-19, 2012.
6)  Hummon AB, Pitt JJ, Camps J, Emons G, Skube SB, Huppi K, Jones TL, Beissbarth T, Kramer F, Grade M, Difilippantonio MJ, Ried T, Caplen NJ.
Systems-wide RNAi analysis of CASP8AP2/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells.
Mol. Cancer. 11: 1, 2012.
7)  Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ.
The 8q24 gene desert: an oasis of non-coding transcriptional activity.
Front Genet. 3: 69, 2012.
8)  Huppi K, Pitt J, Wahlberg B, Caplen NJ.
Genomic instability and mouse microRNAs.
Toxicol. Mech. Methods. 21: 325-33, 2011.
9)  Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ.
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Breast Cancer Res Treat. 130: 663-79, 2011.
10)  Martin SE, Wu Z, Gehlhaus K, Jones TL, Zhang Y, Guha R, Miyamoto S, Pommier Y, Caplen NJ.
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Curr Cancer Drug Targets. 11: 976-86, 2011.
Click Here to View Expanded Bibliography.

This page was last updated on 4/25/2014.